Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
11.08.2022 - $5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) - Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision ...
Source: wallstreet-online.de